Advertisement

Quality of Life Research

, Volume 17, Issue 10, pp 1247–1256 | Cite as

Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community

  • Ariane K. KawataEmail author
  • Dennis A. Revicki
Article

Abstract

Introduction

Symptoms and cognitive impairments of schizophrenia affect social integration and functioning. Accurate measurement is essential in evaluating treatment needs and outcomes. The Personal and Social Performance scale (PSP; Morosini et al. Acta Psychiatrica Scandinavica 101(4):323–329, 2000) is a clinical tool assessing social functioning in rehabilitation settings.

Methods

One hundred and twenty-nine patient/informant dyads at eight US sites participated in this study. Patients were at least 18 years old, have had schizophrenia/schizoaffective disorder for one year or more, and were currently residing in the community. Informants were at least 21 years old, cared for the patient for at least one month, and had contact at least twice weekly. The PSP, Personal Evaluation of Transitions in Treatment (PETiT), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions—Severity (CGI-S), and Quality of Life Scale (QLS) tools were completed. Analyses focused on descriptive statistics, item characteristics, reliability, and validity.

Results

Patients were community-dwelling outpatients without severe difficulties. The PSP scores were well correlated with each other and related measures. Socially useful activities and personal and social relationships were the strongest indicators, suggesting separate aspects of functioning. Internal consistency reliability was adequate (α = 0.76). The PSP was sensitive to differences in social functioning by clinical severity.

Conclusions

The PSP suggested scale reliability and validity among outpatients. Future examination should expand validity analyses and evaluate responsiveness.

Keywords

Schizophrenia Validation Social functioning PSP Personal and Social Performance scale 

Abbreviations

ANOVA

Analysis of variance

CGI-S

Clinical Global Impressions—Severity

DSM-IV

Diagnostic and statistical manual of mental disorders, fourth edition

GAF

Global Assessment of Functioning scale

HRQL

Health-related quality of life

ICC

Intraclass correlation coefficient

IRB

Institutional Review Board

MCID

Minimum clinically important difference

PANSS

Positive and Negative Syndrome Scale

PETiT

Personal Evaluation of Transitions in Treatment

PSP

Personal and Social Performance scale

QLS

Quality of Life Scale

SAS

Statistical Analysis System

SD

Standard deviation

SOFAS

Social and Occupational Functioning Assessment Scale

Trademark

VADO

Skills assessment and definition of goals (translated into English)

Notes

Acknowledgments

This research was sponsored by Wyeth Research, Collegeville, PA. We thank David Strutton, PhD and Arthur S. Zbrozek, MS at Wyeth Research for their support in implementing the study and their helpful comments toward improving this paper. Alan S. Bellack, PhD, ABPP at the University of Maryland and Kim T. Mueser, PhD at New Hampshire-Dartmouth Psychiatric Research Center provided thoughtful review and assistance in the development of a conceptual framework and revision of item content. Jennifer Hanlon, MPH, Sally Mannix, BA, and Meghan Werner, MPP provided project management support throughout the study and Sandra Macker, BS provided statistical programming support. Also, we thank the many staff members who worked on this project at each study site, in particular, José M. Canive, MD, F.R.C.P. and Robin R. Douglas, MA, CCRC at New Mexico VA Healthcare System; Deepak D’Souza, MD and Corie Palazzolo, BA at Connecticut Mental Health Center, Yale University; Robert L. Weisman, DO and Lisa McCartan, MA, CCRC at Strong Ties Community Support Program, University of Rochester Medical Center; Scott Stroup, MD, MPH and Marianne Livingston, LCSW at the University of North Carolina at Chapel Hill; Henry A. Nasrallah, MD and Tracie Northern, MA at Psychiatric Professional Services, Inc., University of Cincinnati Medical Center; Corinne Cather, PhD and Thomas W. Quinlin, BA at North Suffolk Mental Health Association, Freedom Trail Clinic; Irving Belz, MD and Susan Lyngaas, LSW at Tri-County Mental Health Mental Retardation (MHMR) Services; and Saroj Brar, MD and Mira Sugar, RN of Cleveland, OH.

References

  1. 1.
    National Institute of Mental Health (NIMH). (2007). When someone has schizophrenia. Available online at: http://www.nimh.nih.gov/publicat/schizoph.cfm.
  2. 2.
    American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Press.Google Scholar
  3. 3.
    Jablensky, A. (2000). Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience, 250(6), 274–285. doi: 10.1007/s004060070002.PubMedCrossRefGoogle Scholar
  4. 4.
    Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8–19.PubMedGoogle Scholar
  5. 5.
    Regier, D. A., Narrow, W. E., Rae, D. S., Manderscheid, R. W., Locke, B. Z., & Goodwin, F. K. (1993). The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50(2), 85–94.PubMedGoogle Scholar
  6. 6.
    World Health Organization (WHO). (2006). Schizophrenia. Home page at: http://www.who.int/mental_health/management/schizophrenia/en/.
  7. 7.
    Addington, J., & Addington, D. (2000). Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophrenia Research, 44(1), 47–56. doi: 10.1016/S0920-9964(99)00160-7.PubMedCrossRefGoogle Scholar
  8. 8.
    Bell, M. D., & Bryson, G. (2001). Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? Schizophrenia Bulletin, 27(2), 269–279.PubMedGoogle Scholar
  9. 9.
    Bryson, G., & Bell, M. D. (2003). Initial and final work performance in schizophrenia: cognitive and symptom predictors. The Journal of Nervous and Mental Disease, 191(2), 87–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Bryson, G., Bell, M. D., Kaplan, E., & Greig, T. (1998). The functional consequences of memory impairments on initial work performance in people with schizophrenia. The Journal of Nervous and Mental Disease, 186(10), 610–615. doi: 10.1097/00005053-199810000-00004.PubMedCrossRefGoogle Scholar
  11. 11.
    Gaite, L., Vázquez-Barquero, J. L., Borra, C., Ballesteros, J., Schene, A., Welcher, B., et al. (2002). Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatrica Scandinavica, 105(4), 283–292. doi: 10.1034/j.1600-0447.2002.1169.x.PubMedCrossRefGoogle Scholar
  12. 12.
    Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophrenia Bulletin, 26(1), 119–136.PubMedGoogle Scholar
  13. 13.
    Kasckow, J. W., Twamley, E., Mulchahey, J. J., Carroll, B., Sabai, M., Strakowski, S. M., et al. (2001). Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Research, 103(1), 69–78. doi: 10.1016/S0165-1781(01)00260-8.PubMedCrossRefGoogle Scholar
  14. 14.
    McGurk, S. R., Mueser, K. T., Harvey, P. D., LaPuglia, R., & Marder, J. (2003). Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatric Services (Washington, DC), 54(8), 1129–1135. doi: 10.1176/appi.ps.54.8.1129.Google Scholar
  15. 15.
    Palmer, B. W., Heaton, R. K., Gladsjo, J. A., Evans, J. D., Patterson, T. L., Golshan, S., et al. (2002). Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophrenia Research, 55(3), 205–215. doi: 10.1016/S0920-9964(01)00218-3.PubMedCrossRefGoogle Scholar
  16. 16.
    Pinikahana, J., Happell, B., Hope, J., & Keks, N. A. (2002). Quality of life in schizophrenia: a review of the literature from 1995 to 2000. International Journal of Mental Health Nursing, 11(2), 103–111. doi: 10.1046/j.1440-0979.2002.00233.x.PubMedCrossRefGoogle Scholar
  17. 17.
    Sharma, T., & Antonova, L. (2003). Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. The Psychiatric Clinics of North America, 26(1), 25–40. doi: 10.1016/S0193-953X(02)00084-9.PubMedCrossRefGoogle Scholar
  18. 18.
    Burns, T., & Patrick, D. (2007). Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica, 116(6), 403–418. doi: 10.1111/j.1600-0447.2007.01108.x.PubMedCrossRefGoogle Scholar
  19. 19.
    Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica, 101(4), 323–329.PubMedGoogle Scholar
  20. 20.
    Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., et al. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research, 93(1–3), 117–130. doi: 10.1016/j.schres.2007.03.003.PubMedCrossRefGoogle Scholar
  21. 21.
    Kane, J., Canas, F., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research, 90(1–3), 147–161. doi: 10.1016/j.schres.2006.09.012.PubMedCrossRefGoogle Scholar
  22. 22.
    Marder, S. R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., et al. (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry, 62(12), 1363–1370. doi: 10.1016/j.biopsych.2007.01.017.PubMedCrossRefGoogle Scholar
  23. 23.
    Gigantesco, A., Vittorielli, M., Pioli, R., Falloon, I. R. H., Rossi, G., & Morosini, P. (2006). The VADO approach in psychiatric rehabilitation: a randomized controlled trial. Psychiatric Services (Washington, DC), 57(12), 1778–1783. doi: 10.1176/appi.ps.57.12.1778.Google Scholar
  24. 24.
    Bodlund, O., Kullgren, G., Ekselius, L., Lindström, E., & von Knorring, L. (1994). Axis V—Global Assessment of Functioning Scale. Evaluation of a self-report version. Acta Psychiatrica Scandinavica, 90(5), 342–347. doi: 10.1111/j.1600-0447.1994.tb01604.x.PubMedCrossRefGoogle Scholar
  25. 25.
    Hall, R. C. (1995). Global assessment of functioning. A modified scale. Psychosomatics, 36(3), 267–275.PubMedGoogle Scholar
  26. 26.
    Rhee, C. G., & Kim, Y. H. (2006). The newer assessment tools for functionings and the Personal and Social Performance Scale in patients with schizophrenia. Korean Journal of Psychopharmacology, 17(2), 128–142.Google Scholar
  27. 27.
    Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T., Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10(3), 388–398.PubMedGoogle Scholar
  28. 28.
    Vorunganti, L. N., & Awad, A. G. (2002). Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophrenia Research, 56(1–2), 37–46. doi: 10.1016/S0920-9964(01)00161-X.CrossRefGoogle Scholar
  29. 29.
    Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.PubMedGoogle Scholar
  30. 30.
    Guy, W. (1976). The Clinical Global Impression Scale. In ECDEU assessment manual for psychopharmacology (revised). Rockville, MD: National Institute for Mental Health.Google Scholar
  31. 31.
    SAS Institute, Inc. (2002–2003). SAS software, Version 9.1. Cary, NC: SAS Institute, Inc.Google Scholar
  32. 32.
    Cronbach, L. J., & Warrington, W. G. (1951). Time-limit tests: estimating their reliability and degree of speeding. Psychometrika, 16(2), 167–188. doi: 10.1007/BF02289113.PubMedCrossRefGoogle Scholar
  33. 33.
    Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials (2nd ed.). New York: Oxford University Press.Google Scholar
  34. 34.
    Gagnon, D. D., Adriaenssen, I., Nasrallah, H., & Morosini, P. (2006). Reliability, validity, and sensitivity to change of the Personal and Social Performance Scale in patients with stable schizophrenia. Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.United BioSource Corporation, Center for Health Outcomes ResearchBethesdaUSA

Personalised recommendations